 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 1998 | Volume 129 Issue 2 | Pages 94-99
Background: The effect of interferon therapy on the incidence of hepatocellular carcinoma in chronic hepatitis C is poorly defined.
Objective: To compare the incidence of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C to that of historical controls and to examine whether response to therapy is related to incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Design: Retrospective cohort study.
Setting: One university hospital and seven university-affiliated hospitals.
Patients: 419 consecutive patients with chronic hepatitis C who started interferon therapy between January 1992 and December 1993 (interferon group) and 144 patients with chronic hepatitis C who had liver biopsy between January 1986 and December 1989 and did not receive interferon (controls).
Intervention: Patients in the interferon group received human lymphoblastoid interferon, recombinant interferon-
Measurements: The end point was development of hepatocellular carcinoma on abdominal ultrasonography or computed tomography. Sustained response was defined as persistent normalization of alanine aminotransferase (ALT) levels during interferon therapy and follow-up. Relapse was defined as a normal serum ALT level at the end of treatment with an increase to an abnormal level after cessation of treatment. Nonresponse included all other ALT patterns.
Results: Median follow-up in the interferon and control groups was 47.6 and 46.8 months, respectively. During follow-up, hepatocellular carcinoma was found in 28 interferon-treated patients and 19 controls. Cox proportional-hazards regression analysis that included all patients revealed that interferon therapy (P = 0.041), older age (P = 0.003), greater histologic activity (P = 0.029), and higher histologic stage (P = 0.049) were independent factors associated with the development of hepatocellular carcinoma. The risk ratios for development of hepatocellular carcinoma in patients with sustained response, relapse, and nonresponse were 0.06 (95% CI, 0.01 to 0.46), 0.51 (CI, 0.20 to 1.27), and 0.95 (CI, 0.48 to 1.84), respectively, compared with controls.
Conclusions: The incidence of hepatocellular carcinoma was lower in patients with sustained response to interferon therapy than historical controls and nonresponders. Interferon therapy may decrease the risk for hepatocellular carcinoma in patients with chronic hepatitis C.
Author and Article Information
For the Osaka Hepatocellular Carcinoma Prevention Study Group.
ARTICLE
Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
2a, or recombinant interferon- 2b for 6 months.
From Osaka University Medical School, Osaka, Japan.
Acknowledgment: The authors thank Hideaki Tsukuma, MD, for his comments on the manuscript.
Requests for Reprints: Sumio Kawata, MD, Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka 565, Japan.
Current Author Addresses: Drs. Imai and Nishikawa: Department of Internal Medicine, Ikeda Municipal Hospital, 3-1-18 Johnan, Ikeda, Osaka 563, Japan.
This article has been cited by other articles:
|
|
 |
|
  H. Tanaka, Y. Imai, N. Hiramatsu, Y. Ito, K. Imanaka, M. Oshita, T. Hijioka, K. Katayama, I. Yabuuchi, H. Yoshihara, et al. Declining Incidence of Hepatocellular Carcinoma in Osaka, Japan, from 1990 to 2003 Ann Intern Med, June 3, 2008; 148(11): 820 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shiratori, Y. Ito, O. Yokosuka, F. Imazeki, R. Nakata, N. Tanaka, Y. Arakawa, E. Hashimoto, K. Hirota, H. Yoshida, et al. Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival Ann Intern Med, January 18, 2005; 142(2): 105 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B J Veldt, G Saracco, N Boyer, C Camma, A Bellobuono, U Hopf, I Castillo, O Weiland, F Nevens, B E Hansen, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy Gut, October 1, 2004; 53(10): 1504 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Yoshida, R Tateishi, Y Arakawa, M Sata, S Fujiyama, S Nishiguchi, H Ishibashi, G Yamada, O Yokosuka, Y Shiratori, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut, March 1, 2004; 53(3): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hino and K. Okita Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C J. Antimicrob. Chemother., January 1, 2004; 53(1): 19 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-I. Kawamoto, K. Oritani, H. Asada, I. Takahashi, J. Ishikawa, H. Yoshida, M. Yamada, N. Ishida, H. Ujiie, H. Masaie, et al. Antiviral Activity of Limitin against Encephalomyocarditis Virus, Herpes Simplex Virus, and Mouse Hepatitis Virus: Diverse Requirements by Limitin and Alpha Interferon for Interferon Regulatory Factor 1 J. Virol., September 1, 2003; 77(17): 9622 - 9631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Gramenzi, P Andreone, S Fiorino, C Camma, M Giunta, D Magalotti, C Cursaro, C Calabrese, V Arienti, C Rossi, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis Gut, June 1, 2001; 48(6): 843 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishikawa, S. Nishiguchi, S. Shiomi, A. Tamori, N. Koh, T. Takeda, S. Kubo, K. Hirohashi, H. Kinoshita, E. Sato, et al. Somatic Mutation of Mitochondrial DNA in Cancerous and Noncancerous Liver Tissue in Individuals with Hepatocellular Carcinoma Cancer Res., March 1, 2001; 61(5): 1843 - 1845. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. F. Schafer and M. F. Sorrell Conquering Hepatitis C, Step by Step N. Engl. J. Med., December 7, 2000; 343(23): 1723 - 1724. [Full Text]
|
|
|
|
|
|
J. B. Wong and R. S. Koff Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med, November 7, 2000; 133(9): 665 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J L BROWN Interferon therapy reduces the risk for hepatocellular carcinoma Gut, November 1, 2000; 47(5): 610 - 611. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lackner, A. Moser, J. Deutsch, H. H. Kessler, M. Benesch, R. Kerbl, W. Schwinger, H.-J. Dornbusch, K.-H. Preisegger, and C. Urban Interferon-alpha and Ribavirin in Treating Children and Young Adults With Chronic Hepatitis C After Malignancy Pediatrics, October 1, 2000; 106(4): 53e - 53. [Abstract] [Full Text]
|
|
|
|
|
|
F Degos, C Christidis, N Ganne-Carrie, J-P Farmachidi, C Degott, C Guettier, J-C Trinchet, M Beaugrand, and S Chevret Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death Gut, July 1, 2000; 47(1): 131 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shiratori, H. Yoshida, and M. Omata Effects of Interferon Therapy on Inhibition of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis C Jpn. J. Clin. Oncol., May 1, 2000; 30(5): 213 - 214. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Liang, B. Rehermann, L. B. Seeff, and J. H. Hoofnagle Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med, February 15, 2000; 132(4): 296 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Baffis, I. Shrier, A. H. Sherker, and A. Szilagyi Use of Interferon for Prevention of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis B or Hepatitis C Virus Infection Ann Intern Med, November 2, 1999; 131(9): 696 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Prevention of Cancer in the Next Millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research Cancer Res., October 1, 1999; 59(19): 4743 - 4758. [Full Text] [PDF]
|
|
|
|
|
|
H. Yoshida, Y. Shiratori, M. Moriyama, Y. Arakawa, T. Ide, M. Sata, O. Inoue, M. Yano, M. Tanaka, S. Fujiyama, et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan Ann Intern Med, August 3, 1999; 131(3): 174 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Does Interferon Block Hepatocellular Carcinoma in Hepatitis C? Journal Watch (General), July 31, 1998; 1998(731): 4 - 4. [Full Text]
|
|
Article
